Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01368978 · ClinicalTrials.gov registry record · Phase 3

Pediatric Diabetics Type 1 Using InsuPatch

A Phase 3 study of Type 1 Diabetes Mellitus, sponsored by Insuline Medical.

Completed
Registry status
Phase 3
Development phase
27
Enrollment target
1
Study location

NCT01368978 is a Phase 3 study of Type 1 Diabetes Mellitus that has completed, run by Insuline Medical. The registered enrollment target is 27 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01368978, a Phase 3 study of Type 1 Diabetes Mellitus, has completed, sponsored by Insuline Medical.

COMPLETED
Registry status
Phase 3
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

This study is a prospective, single-center, open label, randomized; two-arms cross over study. This is the test protocol for the InsuPatch device, whose purpose is to improve insulin delivery into the blood when the insulin is infused using an insulin-infusion pump by controlled heating of the area surrounding the point of infusion.

Conditions Studied

Interventions

  • DEVICE InsuPatch

Study Locations (1)

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2009-12
Est. Completion 2012-05
Phase Phase 3

Sponsor

Insuline Medical

3 total trials

What the Registry Record Tells You About NCT01368978

The ClinicalTrials.gov registry entry for NCT01368978 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (81% lower). The listed sponsor is Insuline Medical, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which InsuPatch is the first listed.

NCT01368978 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT01368978 about?

NCT01368978 is a clinical study titled "Pediatric Diabetics Type 1 Using InsuPatch". This study is a prospective, single-center, open label, randomized; two-arms cross over study. This is the test protocol for the InsuPatch device, whose purpose is to improve insulin delivery into the blood when the insulin is infused using an insulin-infusion pump by controlled heating of the area...

What is the current status of trial NCT01368978?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2009-12. Estimated completion is 2012-05.

What conditions does trial NCT01368978 study?

This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.

What interventions are being tested in trial NCT01368978?

The interventions under investigation include: InsuPatch (DEVICE).

Who is sponsoring clinical trial NCT01368978?

This trial is sponsored by Insuline Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01368978 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.